• Explore /
  • Poster
  • / Immune responses and clinical outcomes in STAND, a randomized phase 2 study evaluating optimal sequencing of sipuleucel-T (sip-T) and androgen deprivation therapy (ADT) in biochemically-recurrent prostate cancer (BRPC) after local therapy failure.

Immune responses and clinical outcomes in STAND, a randomized phase 2 study evaluating optimal sequencing of sipuleucel-T (sip-T) and androgen deprivation therapy (ADT) in biochemically-recurrent prostate cancer (BRPC) after local therapy failure.

Abstract Poster

Authors

null

Emmanuel S. Antonarakis

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD

Emmanuel S. Antonarakis , Adam S. Kibel , George W. Adams , Lawrence Ivan Karsh , Aymen Elfiky , Neal D. Shore , Nicholas J. Vogelzang , John M. Corman , Johnathan Cartwright Maher , Todd DeVries , Candice McCoy , Nadeem A. Sheikh , Charles G. Drake

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary (Prostate) Cancer

Track

Genitourinary Cancer

Sub Track

Prostate Cancer

Clinical Trial Registration Number

NCT01431391

Citation

J Clin Oncol 33, 2015 (suppl; abstr 5030)

DOI

10.1200/jco.2015.33.15_suppl.5030

Abstract #

5030

Poster Bd #

22

Abstract Disclosures

Similar Posters

First Author: Rahul Raj Aggarwal

First Author: Emmanuel S. Antonarakis

First Author: Rana R. McKay

First Author: E. S. Antonarakis